### Check for updates

### **OPEN ACCESS**

APPROVED BY Frontiers Editorial Office, Frontiers Media SA, Switzerland

\*CORRESPONDENCE Frontiers Production Office production.office@frontiersin.org

RECEIVED 08 June 2023 ACCEPTED 08 June 2023 PUBLISHED 27 June 2023

#### CITATION

Frontiers Production Office (2023) Erratum: Blood B cell depletion reflects immunosuppression induced by live-attenuated infectious bursal disease vaccines. *Front. Vet. Sci.* 10:1236998. doi: 10.3389/fvets.2023.1236998

### COPYRIGHT

© 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Erratum: Blood B cell depletion reflects immunosuppression induced by live-attenuated infectious bursal disease vaccines

## Frontiers Production Office\*

Frontiers Media SA, Lausanne, Switzerland

### KEYWORDS

IBDV, live-attenuated vaccine, vaccine safety, immunosuppression, B cells, replication

### An Erratum on

Blood B cell depletion reflects immunosuppression induced by live-attenuated infectious bursal disease vaccines

by Courtillon, C., Allée, C., Amelot, M., Keita, A., Bougeard, S., Härtle, S., Rouby, J.-C., Eterradossi, N., and Soubies, S. M. (2022). *Front. Vet. Sci.* 9:871549. doi: 10.3389/fvets.2022.871549

Due to a production error, there was a mistake in Figure 3 as published. The text in Figures 3A, B was not displaying correctly. The corrected Figure 3 appears below.

The publisher apologizes for this mistake. The original version of this article has been updated.



### FIGURE 3

Implementation of a modified European Pharmacopoeia-derived protocol for IBDV immunosuppression testing. (A) Layout of animal experiment 3. Extra analyses compared to animal experiments 1 and 2 appear in red text. (B) Percentage of clinically protected chicks observed after velogenic Newcastle Disease Virus challenge. Different letters indicate statistically significant differences (p < 0.05) between groups using Fisher's exact test with FDR adjustment method for multiple pairwise comparisons. (C) Serological response to NDV vaccination during experiment 3. Horizontal bars indicate the median of each group. Different letters indicate statistically significant differences (p < 0.05) between groups using Kruskal-Wallis test. (D) Blood B cell concentrations prior to NDV vaccination ("15 days," left panel), and prior to NDV challenge ("29 days," right panel). Different letters indicate statistically significant differences (p < 0.05) between groups using Kruskal-Wallis test.